Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
Women treated for breast cancer who did more moderate-to-vigorous exercise reported fewer memory problems.
In the GeparSixto study, women with a BRCA1 or BRCA2 mutation responded better to chemotherapy before surgery without carboplatin, while women without a mutation had better outcomes when carboplatin was added to the chemotherapy regimen.
Research suggests that treatment with chemotherapy and radiation at the same time can help keep breast cancer from coming back.
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
Women diagnosed with metastatic breast cancer who got Avastin in combination with chemotherapy lived 1 to 3 months longer without the cancer growing compared to women who only got chemotherapy, but overall survival was the same for both groups.
Research shows no link between progression-free survival and overall survival in experimental breast cancer treatment trials.
A small study suggests that hormonal therapy medicines may contribute to chemo brain more than chemotherapy does.
A study suggests that women diagnosed with hormone-receptor-negative, early-stage breast cancer who were treated with Zoladex in addition to chemotherapy before surgery were much less likely to be infertile after chemotherapy ended.
A study suggests that treating even early-stage breast cancer in Black women with chemotherapy before surgery can help reduce their risk of recurrence.
Updated results show adding Perjeta to Herceptin and chemotherapy after surgery for early-stage HER2-positive breast cancer continues to reduce the risk of recurrence and to slightly improve survival.
Neuropathy caused by chemotherapy increases the risk of falling.
Women diagnosed with breast cancer may have a higher risk of a type of heart problem called atrial fibrillation, according to a retrospective Danish study.
ASCO updates guidelines on using biomarkers to make decisions about systemic therapies after surgery to treat people diagnosed with early-stage invasive breast cancer to include recent results from the TAILORx trial on using the Oncotype DX test to guide use of chemotherapy after surgery.
For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.
A study suggests that the Oncotype DX test can offer relevant information about cancer progression and 2-year survival rates for women diagnosed with de novo stage IV cancer.
A study suggests the MammaPrint test can help estimate the risk of recurrence after surgery for early-stage disease.
Early results suggest that an anthracycline chemotherapy regimen is better than a regimen without an anthracycline for early-stage, HER2-negative disease with a high risk of recurrence.
Freezing embryos created from eggs extracted before treatment allowed women diagnosed with early-stage breast cancer to become pregnant at rates similar to women not diagnosed with breast cancer who underwent in vitro fertilization.
Research shows that women older than 65 do better on standard intravenous chemotherapy after surgery to remove early-stage breast cancer than Xeloda (chemical name: capecitabine), an oral chemotherapy.
A test that measures circulating tumor cells in the blood may help doctors more accurately determine the risk of breast cancer recurrence.
Women treated with chemotherapy for breast cancer were no more likely to be infected with COVID-19 or die from COVID-19 than women treated with other medicines that don’t weaken the immune system.